Clinical Trials · NCT02889393
Teduglutide for Enterocutaneous Fistula (ECF)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Daniel Dante Yeh
- Enrollment
- 6
- Start date
- Jan 2019
- Locations
- 1 site, United States
- Primary endpoint
- Change in Average 3-day Fistula Percent Volume